Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | GUSB | P08236 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23733438 | 1.00 | EBP (0.38) | EBPSIGMAR1FDPSLMNADNM1 | |
| SCHEMBL24555502 | 0.87 | EBP (0.38) | EBPSIGMAR1FDPSLMNADNM1 | |
| SCHEMBL19099370 | 0.83 | EBP (0.36) | EBPSIGMAR1FDPSLMNADNM1 | |
| SCHEMBL22458069 | 0.83 | EBP (0.36) | EBPSIGMAR1FDPSLMNADNM1 | |
| SCHEMBL19491825 | 0.82 | EBP (0.56) | EBPSIGMAR1FDPSLMNA | |
| SCHEMBL13186193 | 0.82 | EBP (0.56) | EBPSIGMAR1FDPSLMNA | |
| SCHEMBL23717144 | 0.82 | EBP (0.56) | EBPSIGMAR1FDPSLMNA | |
| SCHEMBL23765250 | 0.81 | FDPS (0.36) | EBPSIGMAR1FDPSLMNADNM1 | |
| SCHEMBL19251213 | 0.81 | GNAI3 (0.40) | FDPSLMNADNM1OPRM1 | |
| SCHEMBL18625032 | 0.81 | FDPS (0.36) | EBPSIGMAR1FDPSLMNADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | EBP 3032/4885SIGMAR1 4573/4885FDPS 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.